Современные подходы к ведению пациентов с бронхоэктазией
https://doi.org/10.18093/0869-0189-2020-30-1-81-91
Аннотация
Об авторе
Э. Х. АнаевРоссия
Анаев Эльдар Хусеевич – д. м. н., профессор кафедры пульмонологии
117997, Москва, ул. Островитянова, 1
тел.: (910) 434-76-92
Список литературы
1. Polverino E., Goeminne P.C., McDonnell M.J. et al. European Respiratory Society guidelines for the management of adult bronchiectasis. Eur. Respir. J. 2017; 50 (3): pii: 1700629. DOI: 10.1183/13993003.00629-2017.
2. Pasteur M.C., Bilton D., Hill A.T. British Thoracic Society guidelines for non-CF bronchiectasis. Thorax. 2010; 65 (Suppl. 1): i1–58. DOI: 10.1136/thx.2010.136119.
3. Chandrasekaran R., Mac Aogáin M., Chalmers J.D. et al. Geographic variation in the aetiology, epidemiology and microbiology of bronchiectasis. BMC. Pulm. Med. 2018; 18 (1): 83. DOI: 10.1186/s12890-018-0638-0.
4. Чучалин А.Г., ред. Респираторная медицина: руководство в 3 т. 2-е изд., перераб. и доп. М.: Литтерра; 2017. Т. 1.
5. Quint J.K., Millett E.R., Joshi M. et al. Changes in the incidence, prevalence and mortality of bronchiectasis in the UK from 2004 to 2013: a population-based cohort study. Eur. Respir. J. 2016; 47 (1): 186–193. DOI: 10.1183/13993003.01033-2015.
6. Contarini M., Finch S., Chalmers J.D. Bronchiectasis: a case-based approach to investigation and management. Eur. Respir. Rev. 2018; 27 (149): 180016. DOI: 10.1183/16000617.0016-2018.
7. Altenburg J., Wortel K., van der Werf T.S., Boersma W.G. Non-cystic fibrosis bronchiectasis: clinical presentation, diagnosis and treatment, illustrated by data from a Dutch Teaching Hospital. Neth. J. Med. 2015; 73 (4): 147–154.
8. Smith M.P. Diagnosis and management of bronchiectasis. CMAJ. 2017; 189 (24): E828–835. DOI: 10.1503/cmaj.160830.
9. Finch S., McDonnell M.J., Abo-Leyah H. et al. A comprehensive analysis of the impact of Pseudomonas aeruginosa colonization on prognosis in adult bronchiectasis. Ann. Am. Thorac. Soc. 2015; 12 (11): 1602–1611. DOI: 10.1513/AnnalsATS.201506-333OC.
10. Shoemark A., Ozerovitch L., Wilson R. Aetiology in adult patients with bronchiectasis. Respir. Med. 2007; 101 (6): 1163–1170.
11. Pasteur M.C., Helliwell S.M., Houghton S.J. et al. An investigation into causative factors in patients with bronchiectasis. Am. J. Respir. Crit. Care. Med. 2000; 162 (4, Pt 1): 12771284. DOI: 10.1164/ajrccm.162.4.9906120.
12. Зимина В.Н., Дегтярева С.Ю., Белобородова Е.Н. и др. Микобактериозы: современное состояние проблемы. Клиническая микробиология и антимикробная химиотерапия. 2017; 19 (4): 276–282. Доступно на: https://cyberleninka.ru/article/n/mikobakteriozy-sovremennoe-sostoyanie-problemy/viewer
13. Anwar G.A., McDonnell M.J., Worthy S.A. et al. Phenotyping adults with non-cystic fibrosis bronchiectasis: a prospective observational cohort study. Respir. Med. 2013; 107 (7): 1001–1007. DOI: 10.1016/j.rmed.2013.04.013.
14. Lonni S., Chalmers J.D., Goeminne P.C. et al. Etiology of non-cystic fibrosis bronchiectasis in adults and its correlation to disease severity. Ann. Am. Thorac. Soc. 2015; 12 (12): 1764–1770. DOI: 10.1513/AnnalsATS.201507-472OC.
15. Cartier Y., Kavanagh P.V., Johkoh T. et al. Bronchiectasis: accuracy of high-resolution CT in the differentiation of specific diseases. Am. J. Roentgenol. 1999; 173: 47–52.
16. Bush A., Floto R.A. Pathophysiology, causes and genetics of paediatric and adult bronchiectasis. Respirology. 2019; 24 (11): 1053–1062. DOI: 10.1111/resp.13509.
17. Kousha M., Tadi R., Soubani A.O. Pulmonary aspergillosis: a clinical review. Eur. Respir. Rev. 2011; 20 (121): 156–174. DOI: 10.1183/09059180.00001011.
18. Eaton T., Garrett J., Milne D. et al. Allergic bronchopulmonary aspergillosis in the asthma clinic. A prospective evaluation of CT in the diagnostic algorithm. Chest. 2000; 118(1): 66–72. DOI: 10.1378/chest.118.1.66.
19. Stevens D.A., Moss R.B., Kurup V.P. et al. Allergic bronchopulmonary aspergillosis in cystic fibrosis – state of the art: Cystic Fibrosis Foundation Consensus Conference. Clin. Infect. Dis. 2003; 37 (Suppl. 3): S225–264. DOI: 10.1086/376525.
20. Kelly M.G., Murphy S., Elborn J.S. Bronchiectasis in secondary care: a comprehensive profile of a neglected disease. Eur. J. Intern. Med. 2003; 14 (8): 488–492. DOI: 10.1016/j.ejim.2003.10.002.
21. Patterson K., Strek M.E. Allergic bronchopulmonary aspergillosis. Proc. Am. Thorac. Soc. 2010; 7 (3): 237–244. DOI: 10.1513/pats.200908-086AL.
22. Patterson K.C., Strek M.E. Diagnosis and treatment of pulmonary aspergillosis syndromes. Chest. 2014; 146 (5): 1358–1368. DOI: 10.1378/chest.14-0917.
23. Mitchell T.A., Hamilos D.L., Lynch D.A., Newell J.D. Distribution and severity of bronchiectasis in allergic bronchopulmonary aspergillosis (ABPA). J. Asthma. 2000; 37 (1): 65–72. DOI: 10.3109/02770900009055429.
24. Greenberger P.A., Miller T.P., Roberts M., Smith L.L. Allergic bronchopulmonary aspergillosis in patients with and without evidence of bronchiectasis. Ann. Allergy. 1993; 70 (4): 333–338.
25. Patterson R., Greenberger P.A., Radin R.C., Roberts M. Allergic bronchopulmonary aspergillosis: staging as an aid to management. Ann. Intern. Med. 1982; 96 (3): 286–291. DOI: 10.7326/0003-4819-96-3-286.
26. Agarwal R. Allergic bronchopulmonary aspergillosis. Chest. 2009; 135 (3): 805–826. DOI: 10.1378/chest.08-2586.
27. Stevens D.A., Schwartz H.J., Lee J.Y. et al. A randomized trial of itraconazole in allergic bronchopulmonary aspergillosis. N. Engl. J. Med. 2000; 342 (11): 756–762. DOI: 10.1056/NEJM200003163421102.
28. Agarwal R., Dhooria S., Singh Sehgal I. et al. A randomized trial of itraconazole vs prednisolone in acute-stage allergic bronchopulmonary aspergillosis complicating asthma. Chest. 2018; 153 (3): 656–664. DOI: 10.1016/j.chest.2018.01.005.
29. Stern B.M., Sharma G. Ciliary Dysfunction (Kartagener Syndrome, Primary Ciliary Dyskinesia). StatPearls [Internet]. Treasure Island (FL): Stat Pearls Publishing; 2019.
30. Barbato A., Frischer T., Kuehni C.E. et al. Primary ciliary dyskinesia: a consensus statement on diagnostic and treatment approaches in children. Eur. Respir. J. 2009; 34 (6): 1264–1276. DOI: 10.1183/09031936.00176608.
31. Noone P.G., Leigh M.W., Sannuti A. et al. Primary ciliary dyskinesia: diagnostic and phenotypic features. Am. J. Respir. Crit. Care. Med. 2004; 169 (4): 459–467. DOI: 10.1164/rccm.200303-365OC.
32. Vanaken G.J., Bassinet L., Boon M. et al. Infertility in an adult cohort with primary ciliary dyskinesia: phenotypegene association. Eur. Respir. J. 2017; 50 (5): pii: 1700314. DOI: 10.1183/13993003.00314-2017.
33. Lucas J.S., Barbato A., Collins S.A. et al. European Respiratory Society guidelines for the diagnosis of primary ciliary dyskinesia. Eur. Respir. J. 2017; 49 (1): pii: 1601090. DOI: 10.1183/13993003.01090-2016.
34. Behan L., Dimitrov B.D., Kuehni C.E. et al. PICADAR: a diagnostic predictive tool for primary ciliary dyskinesia. Eur. Respir. J. 2016; 47 (4): 1103–1112. DOI: 10.1183/13993003.01551-2015.
35. Kennedy M.P., Noone P.G., Leigh M.W. et al. High-resolution CT of patients with primary ciliary dyskinesia. Am. J. Roentgenol. 2007; 188 (5): 1232–1238. DOI: 10.2214/AJR.06.0965.
36. Shah A., Shoemark A., MacNeill S.J. et al. A longitudinal study characterizing a large adult primary ciliary dyskinesia population. Eur. Respir. J. 2016; 48 (2): 441–450. DOI: 10.1183/13993003.00209-2016.
37. Shapiro A.J., Zariwala M.A., Ferkol T. et al. Diagnosis, monitoring, and treatment of primary ciliary dyskinesia: PCD foundation consensus recommendations based on state of the art review. Pediatr. Pulmonol. 2016; 51 (2): 115–132. DOI: 10.1002/ppul.23304.
38. Reiff D.B., Wells A.U., Carr D.H. et al. CT findings in bronchiectasis: limited value in distinguishing between idiopathic and specific types. Am. J. Roentgenol. 1995; 165 (2): 261–267. DOI: 10.2214/ajr.165.2.7618537.
39. Wong C., Jayaram L., Karalus N. et al. Azithromycin for prevention of exacerbations in non-cystic fibrosis bronchiectasis (EMBRACE): a randomized, double-blind, placebocontrolled trial. Lancet. 2012; 380 (9842): 660–667. DOI: 10.1016/S0140-6736(12)60953-2.
40. Serisier D.J., Martin M.L., McGuckin M.A. et al. Effect of long-term, low-dose erythromycin on pulmonary exacerbations among patients with non-cystic fibrosis bronchiectasis: the BLESS randomized controlled trial. JAMA. 2013; 309(12): 1260–1267. DOI: 10.1001/jama.2013.2290.
41. Haworth C.S., Foweraker J.E., Wilkinson P. et al. Inhaled colistin in patients with bronchiectasis and chronic Pseudomonas aeruginosa infection. Am. J. Respir. Crit. Care Med. 2014; 189 (8): 975–982. DOI: 10.1164/rccm.2013122208OC.
42. Serisier D.J., Bilton D., De Soyza A. et al. Inhaled, dual release liposomal ciprofloxacin in non-cystic fibrosis bronchiectasis (ORBIT-2): a randomized, double-blind, placebo-controlled trial. Thorax. 2013; 68 (9): 812–817. DOI: 10.1136/thoraxjnl-2013-203207.
43. Анаев Э.Х. Современные подходы к лечению бронхоэктазии у взрослых. Практическая пульмонология. 2017; (4): 30–38.
44. Kellett F., Robert N.M. Nebulised 7% hypertonic saline improves lung function and quality of life in bronchiectasis. Respir. Med. 2011; 105 (12): 1831–1835. DOI: 10.1016/j.rmed.2011.07.019.
45. Bilton D., Tino G., Barker A.F. et al. Inhaled mannitol for non-cystic fibrosis bronchiectasis: a randomized, controlled trial. Thorax. 2014; 69 (12): 1073–1079. DOI: 10.1136/thoraxjnl-2014-205587.
46. Herrero-Cortina B., Alcaraz V., Vilaro J. et al. Impact of hypertonic saline solutions on sputum expectoration and their safety profile in patients with bronchiectasis: a randomized crossover trial. J. Aerosol. Med. Pulm. Drug Deliv. 2018; 31 (5): 281–289. DOI: 10.1089/jamp.2017.1443.
47. Murray M.P., Pentland J.L., Hill A.T. A randomized crossover trial of chest physiotherapy in non-cystic fibrosis bronchiectasis. Eur. Respir. J. 2009; 34 (5): 1086–1092. DOI: 10.1183/09031936.00055509.
48. Nicolini A., Cardini F., Landucci N. et al. Effectiveness of treatment with high-frequency chest wall oscillation in patients with bronchiectasis. BMC. Pulm. Med. 2013; 13: 21. DOI: 10.1186/1471-2466-13-21.
49. Lee A.L., Hill C.J., Cecins N. et al. Minimal important difference in field walking tests in non-cystic fibrosis bronchiectasis following exercise training. Respir. Med. 2014; 108 (9): 1303–1309. DOI: 10.1016/j.rmed.2014.07.006.
50. Zanini A., Aiello M., Adamo D. et al. Effects of pulmonary rehabilitation in patients with non-cystic fibrosis bronchiectasis: a retrospective analysis of clinical and functional predictors of efficacy. Respiration. 2015; 89 (6): 525–533. DOI: 10.1159/000380771.
Рецензия
Для цитирования:
Анаев Э.Х. Современные подходы к ведению пациентов с бронхоэктазией. Пульмонология. 2020;30(1):81-91. https://doi.org/10.18093/0869-0189-2020-30-1-81-91
For citation:
Anaev E.Kh. Modern approaches to the management of patients with bronchoectasia. PULMONOLOGIYA. 2020;30(1):81-91. (In Russ.) https://doi.org/10.18093/0869-0189-2020-30-1-81-91